Johnson Pharmacare Limited, a pharmaceutical company, has reported its unaudited financial results for the quarter and half year ended September 30, 2025. The company's Board of Directors approved these results during a meeting held on November 14, 2025.

Financial Performance

The company reported a loss before tax of Rs. 5.68 lakhs for the six-month period ending September 30, 2025. This financial performance indicates ongoing challenges for Johnson Pharmacare in the current fiscal year.

Key Financial Metrics

Based on the available income statement data, here's a breakdown of Johnson Pharmacare's financial performance:

Analysis of Results

Revenue

The company reported zero revenue for the quarter, compared to a negative revenue of Rs. 0.30 crore in the previous quarter. This suggests a complete halt in sales or a potential accounting adjustment.

EBITDA

The Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) showed a loss of Rs. 0.10 crore, an improvement from the Rs. 0.50 crore loss in the previous quarter.

Net Profit

Johnson Pharmacare's net loss narrowed to Rs. 0.10 crore, compared to a loss of Rs. 0.50 crore in the previous quarter, indicating some improvement in overall financial performance.

Earnings Per Share (EPS)

The EPS improved from -0.01 in the previous quarter to 0.00 in the current quarter, aligning with the reduced net loss.

Audit Status

The company's statutory auditors have completed a limited review of these financial results, as stated in the announcement.

Outlook

While the narrowing losses suggest some improvement in Johnson Pharmacare's financial health, the absence of revenue in the current quarter raises concerns about the company's operational status and market positioning. Investors and stakeholders may need to closely monitor future announcements for more clarity on the company's strategic direction and plans to return to profitability.

The pharmaceutical sector often faces challenges related to research and development costs, regulatory approvals, and market competition. Johnson Pharmacare's performance should be viewed in the context of these industry-wide factors.

Investors are advised to conduct their own research and consider seeking professional financial advice before making investment decisions based on these results.

Johnson Pharmacare Limited , a pharmaceutical company, has announced a significant change in its board composition. The company's Board of Directors has accepted the resignation of Mr. Paresh Sengal from his position as Director, effective October 27, 2025.

Resignation Details

Mr. Sengal cited preoccupation with other work as the reason for his departure. In his resignation letter, he expressed gratitude to his fellow board members for their cooperation during his tenure as Director.

Board Meeting Particulars

The decision was made during a board meeting held at the company's registered office. Here are the key details of the meeting:

Company Information

Johnson Pharmacare Limited, formerly known as Sun and Shine Worldwide Limited, is listed on the BSE with the following details:

The company's registered office is located at the Regus Business Centre, Privilon, East Wing, 2nd Floor, Sarkhej Gandhinagar Highway, Bodakdev, Ahmedabad, Gujarat, India - 380054.

This board change comes as part of the company's ongoing corporate governance processes. The company has duly informed the BSE about this development, in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Investors and stakeholders are advised to take note of this change in the company's leadership structure.